Bevacizumab or Bevacizumab biosimilar
Preclinical
BeiGeneBevacizumab or Bevacizumab biosimilar is one of 4 therapeutic programs targeting Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
3
Competitors
Pipeline
Status by Indication[2][1]
Indication
Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal CancerPreclinical
Active, not recruiting
Competition
Competitive Landscape
3 competitors in Unresectable or Metastatic Microsatellite Stable/mismatch Repair Proficient Colorectal Cancer
#DrugCompanyPhaseTrials
1Beyfortus
BeiGenePreclinical
Fluoropyrimidine
RochePreclinical
Alcestobart
BeiGenePreclinical
Bevacizumab or Bevacizumab biosimilar
BeiGenePreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Unresectable or Metastatic Microsatellite Stable/Mismatch Repair Proficient Colorectal Cancer1 trial
Sources
References
- [1]
- [2]
- [3]